11.08.2022 - Company is investigating efzofitimod in global pivotal Phase 3 EFZO-FIT study in pulmonary sarcoidosis patientsSAN DIEGO, Aug. 11, 2022 (GLOBE NEWSWIRE) - aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or “the Company”), a clinical stage biotherapeutics . Seite 1